Attached files
file | filename |
---|---|
EX-99.1 - EXHIBIT 99.1 - OMNI BIO PHARMACEUTICAL, INC. | c10414exv99w1.htm |
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 30, 2010
Omni Bio Pharmaceutical,
Inc.
(Exact name of registrant as
specified in its charter)
Colorado | 000-52530 | 20-8097969 | ||
(State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
5350 South Roslyn, Suite 430,
Greenwood Village, CO |
80111 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (303) 867-3415
(Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On January 4, 2011, Omni Bio Pharmaceutical, Inc. issued a press release announcing that U.S. Patent No. 7,850,970, entitled “Inhibitors of Serine Protease Activity and Their Use in Methods and Compositions for Treatment of Bacterial Infections,” was issued by the United States Patent and Trademark Office. A copy of the press release is furnished herewith as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 | Press Release of Omni Bio Pharmaceutical, Inc. dated January 4, 2011 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Omni Bio Pharmaceutical, Inc.
Date: January 4, 2011
Robert C.
Ogden
Chief Financial Officer
3
Exhibit Index
Exhibit No. | Description | |
99.1
|
Press Release of Omni Bio Pharmaceutical, Inc. dated January 4, 2011 |
4